ArticleObesity surgery2024
Medium-Term Outcomes from a Series of 1000 One Anastomosis Gastric Bypass in Australia: A Case Series.
Article in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Mapping the Landscape of Marginal Ulcers After One Anastomosis Gastric Bypass: Incidence, Regional Trends, and Treatment Insights from a Systematic Review and Meta-analysis.Obesity surgery · 2025Pooled it
- Three-Year Outcomes of Reflux Esophagitis and Late Complications After FundoRing Versus Standard One-Anastomosis Gastric Bypass: a Randomized Controlled Trial.Obesity surgery · 2026Trial
- Comparison of Dumping Syndrome After FundoRing and Standard One-anastomosis Gastric Bypass: A Randomized Controlled Trial.Obesity surgery · 2026Trial
- Effects of training in pairs versus training alone on reaching proficiency in minimally invasive Roux-en-Y-gastric bypass on a virtual reality trainer in medical students: a randomized-controlled trial.Surgical endoscopy · 2025Trial
- Cost-effectiveness analysis of FundoRing versus standard one-anastomosis gastric bypass: up to 3-year results of a randomized controlled trial.Annals of medicine and surgery (2012) · 2026Article
- Scoping Review of Reflux after Primary One Anastomosis Gastric Bypass: Navigating the Maze to Enhance the Evidence Base.Obesity surgery · 2026Article
- Reflux After One Anastomosis Gastric Bypass: Why The Debates Remain? An Agenda For Action and Call For Collaboration.Obesity surgery · 2025Review
- Reply to Pantelis, A.G. Comment on "Salazar et al. Weight Regain after Metabolic Surgery: Beyond the Surgical Failure.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study presents the short- (less than 6 months) and medium-term (6 months to 2 years) outcomes for weight loss and type 2 diabetes mellitus (T2DM) for all patients undergoing one anastomosis gastric bypass (OAGB) across multiple institutions between 2015 and 2021. MATERIALS AND
methodsA retrospective analysis of prospectively collected databases was performed including 1022 participants who underwent OAGB at multiple institutions by multiple surgeons between 2015 and 2021. Primary outcome was percentage total weight loss (TWL) and secondary outcomes were achieving resolution of T2DM; OAGB specific short- and medium-term complications including bile reflux, marginal ulceration and internal herniation.
resultsOne thousand and twenty-two patients underwent OAGB (81% primary surgery). A percentage of 34.1% (n = 349) had a preoperative diagnosis of type 2 diabetes mellitus (T2DM). Mean TWL was 33.6 ± 9% with a T2DM remission rate of 74% at 1-year post-op. Rates of bile reflux and marginal ulceration was 1.1% (n = 11) and 1.1% (n = 11). There were no cases of internal herniation during the follow-up period.
conclusionOAGB results has echoed previously published work as being efficacious and safe in a short-medium term. The prevalence of complications, especially bile reflux is overall low in our population and no current evidence exists to support an increased risk of metaplasia or malignancy related to bile within the stomach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.